Startups

Character Biosciences
Character Biosciences develops precision medicines for progressive polygenic diseases, initially focusing on age-related macular degeneration and primary open-angle glaucoma. It combines human genetics, longitudinal clinical data, retinal imaging and AI-driven modeling to identify disease subtypes, discover therapeutic targets and select patients for clinical trials. Its pipeline includes CTX114, a complement inhibitor for geographic atrophy, and CTX203, a lipid modulator intended to prevent progression to advanced age-related macular degeneration.


